Literature DB >> 6723758

Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

M M Hammarlund, L K Paalzow, B Odlind.   

Abstract

Furosemide 40 mg was administered to 8 healthy subjects as an i.v. bolus dose, as 1 tablet in the fasting state, and as 1 tablet and a solution after food intake. The i.v. data gave a total body clearance of 162 +/- 10.8 ml/min and a renal clearance of 117 +/- 11.3 ml/min; the volume of distribution at steady state was 8.3 +/- 0.61. Oral administration gave a bio-availability of the tablet (fasting) of 51%. Food intake slightly reduced the bioavailability, but not to a significant extent. There was no significant difference in availability between the tablet and the solution. Moment analysis gave a mean residence time after the i.v. dose, MRTi .v., of 51 +/- 1.5 min. The mean absorption times (MAT) for all oral doses were significantly longer than the MRTi .v., indicating absorption rate-limited kinetics of furosemide. On average, food delayed the absorption by 60 min. The MAT for the tablet in the postprandial state was significantly longer than for the solution, indicating dissolution rate-limited absorption of the tablet.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723758     DOI: 10.1007/BF00630286

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of Lasix.

Authors:  W Rupp
Journal:  Scott Med J       Date:  1974       Impact factor: 0.729

3.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

4.  Kinetics of acetaminophen absorption and gastric emptying in man.

Authors:  J A Clements; R C Heading; W S Nimmo; L F Prescott
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

5.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

6.  Dose-dependent pharmacokinetics of furosemide in the rat.

Authors:  M M Hammarlund; L K Paalzow
Journal:  Biopharm Drug Dispos       Date:  1982 Oct-Dec       Impact factor: 1.627

7.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

8.  The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.

Authors:  F Andreasen; C K Christensen; F K Jakobsen; C E Mogensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-09

9.  Disposition and absolute bioavailability of furosemide in healthy males.

Authors:  E S Waller; S F Hamilton; J W Massarella; M A Sharanevych; R V Smith; G J Yakatan; J T Doluisio
Journal:  J Pharm Sci       Date:  1982-10       Impact factor: 3.534

10.  The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects.

Authors:  F Andreasen; C K Christensen; F K Jacobsen; J Jansen; C E Mogensen; O L Pedersen
Journal:  Eur J Clin Invest       Date:  1982-06       Impact factor: 4.686

View more
  32 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

4.  Response to furosemide during dehydration with and without naproxen pretreatment of kidney donors and renal transplant recipients.

Authors:  P A Sjöström; B G Odlind; M Hammarlund-Udenaes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

6.  Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

Authors:  A B Suttle; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

7.  Applications and simulations of a discontinuous oral absorption pharmacokinetic model.

Authors:  J W Witcher; F D Boudinot
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

8.  Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs.

Authors:  V Mummaneni; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

9.  Sublingual administration of furosemide: new application of an old drug.

Authors:  Laurent Haegeli; Hans Peter Brunner-La Rocca; Markus Wenk; Matthias Pfisterer; Jürgen Drewe; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

10.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.